Pyrrolo[1,2-b]pyridazin-2-ones as potent inhibitors of HCV NS5B polymerase
Graphical abstract
Section snippets
Acknowledgments
The authors thank Drs. Devron Averett and Steve Worland for their support and helpful discussions during the course of this work.
References and notes (16)
- et al.
J. Med. Chem.
(2007)et al.J. Biol. Chem.
(2002)et al.Bioorg. Med. Chem. Lett.
(2006)(d)Blake, J. F.; Fell, J. B.; Fischer, J. P.; Hendricks, R. T.; Spencer, S. R.; Stengel, P. J. WO2006117306,... et al.Bioorg. Med. Chem. Lett.
(2005)(f)Hutchinson, D. K. et al. U.S. Patent US2005107364,... - Ruebsam, F.; Tran, M. T.; Webber, S. E.; Dragovich, P. S.; Li, L.-S.; Murphy, D. E.; Kucera, D. J.; Sun, Z.; Tran, C....
- et al.
Tetrahedron Lett.
(2005) Hepatology
(2002)et al.N. Engl. J. Med.
(1999)et al.J. Hepatol.
(2003)- et al.
Science
(1972)et al.Adv. Virus Res.
(1993) - et al.
N. Eng. J. Med.
(2007) - et al.
Science
(1997)
Cited by (38)
Design and development of HCV NS5B polymerase inhibitors
2017, Viral Proteases and Their InhibitorsComputational predictions suggest that structural similarity in viral polymerases may lead to comparable allosteric binding sites
2016, Virus ResearchCitation Excerpt :Biochemical experiments combined with computational studies provide insight into how inhibitors bound to the HCV NNI-2 and NNI-3 pockets achieve allosteric inhibition. Both NNI-2 and NNI-3 inhibitors have been shown to disrupt an early stage of replication that precedes elongation (Ruebsam et al., 2008; Ontoria et al., 2009). Molecular simulations by our group suggest that inhibitors of the NNI-2 and NNI-3 pockets generally restrict protein fluctuations and disrupt motions observed in the free enzyme (Davis and Thorpe 2013; Brown and Thorpe, 2015; Davis et al., 2015).
The therapeutic journey of pyridazinone
2016, European Journal of Medicinal ChemistryCitation Excerpt :Ellis et al. reported pyridazinone bearing compound, 68 as a potent inhibitor of HCV NS5B enzyme with IC50 value of less than 10 nM and CE50 of 1.1 nM [95]. Amongst the pyridazinone analogs prepared by Ruebsam et al., compound 69 displayed excellent potency against genotype 1 HCV NS5B polymerase [96]. Li et al. optimized, physical properties and pharmacokinetics parameters of pyridazinone moiety in a review article.
Allosteric inhibitors have distinct effects, but also common modes of action, in the HCV polymerase
2015, Biophysical JournalCitation Excerpt :We confirmed that the ligands remained bound to the enzyme throughout the simulations via visual inspection of each trajectory. Fig. 1 shows the structures of each ligand and their corresponding IC50 values (19,21–24). Overall, ligand binding shifts the conformational sampling of the enzyme compared to the free structures, which is demonstrated by the distributions of interdomain angles (θ) and template channel widths shown in Fig. 2.
Recent advances in drug discovery of benzothiadiazine and related analogs as HCV NS5B polymerase inhibitors
2011, Bioorganic and Medicinal Chemistry